Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model

Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model

Abstract Background Physical activity is known to have anti-cancer effects, including immunomodulatory actions. This study investigated the hypothesis that physical activity synergizes with combined lenvatinib plus anti-PD-1 therapy to enhance efficacy in patients with unresectable HCC. Methods The...

Full description

Bibliographic Details
Main Authors: Xue-Feng Liu, Xiao-Dong Zhu, Long-Hai Feng, Xiao-Long Li, Bin Xu, Kang-Shuai Li, Nan Xiao, Ming Lei, Hui-Chuan Sun, Zhao-You Tang
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Experimental Hematology & Oncology
Subjects:
Hepatocellular carcinoma
Physical activity
Anti-PD-1
Lenvatinib
Online Access:https://doi.org/10.1186/s40164-022-00275-0

Internet

https://doi.org/10.1186/s40164-022-00275-0

Similar Items